Skip to content
Screener

D&A at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$163.4M+1.7%
Bioventus logo
BioventusBVS
$1.04M-27.7%
Globus Medical logo
Globus MedicalGMED
$29.56M-2.1%
CONMED logo
CONMEDCNMD
$7.24M-16.8%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$508K-56.5%
Encompass Health Corporation logo
Encompass Health CorporationEHC
$87.3M+10.2%

Segments

By segment

See full
Reconstructive$23.69M-1.1%
Prevention & Recovery$5.13M

Other financials

Income statement

See full
Revenue$582.8M+3.2%
Gross profit$359.2M+7.3%
Operating income$17.4M+204%
Net income-$1.2M+96.8%
EPS (diluted)-$0.02+96.9%

Balance sheet

See full
Cash & equivalents$12.6M-71.5%
Total debt$1.3B-6.4%
Total equity$1.5B-42.7%
Total assets$3.8B-25.0%

Cash flow

See full
Operating cash flow$75.0M+57.1%
CapEx$43.9M-1.1%
Free cash flow$31.1M

Valuation

See full
Market cap$1.53B-5.5%
Enterprise value$2.83B-4.9%
P/S0.7×-0.1×

Profitability

See full
Gross margin61.1%+3.5pp
Operating margin-45.1%+19.4pp
Net margin-48%+17.7pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-54.3%+672pp
Debt / equity0.9×+0.3×
Current ratio-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001420800-26-000035
Line itemThree Months Ended / July 3, 2026Three Months Ended / July 4, 2025Six Months Ended / July 3, 2026Six Months Ended / July 4, 2025
Gross profit359,249334,697724,734666,926
Selling, general and administrative expense263,730267,074546,540536,093
Research and development expense31,68630,70063,21959,228
Amortization of acquired intangibles41,56142,96283,46584,774
Purchase of royalty interest10,04145,818
Restructuring charges4,8597167,5674,578
Operating income (loss)17,413(16,796)23,943(63,565)
Interest expense, net8,0389,29417,20718,482

Item 1. Financial Statements

FAQ

What is Enovis's D&A?
Enovis (ENOV) reported D&A of $41.56M in Q2 2026.
How has Enovis's D&A changed year-over-year?
Enovis's D&A decreased by 3.3% year-over-year, from $42.96M to $41.56M.
What is the long-term trend for Enovis's D&A?
Over 4 years (2021 to 2025), Enovis's D&A has grown at a -2.0% compound annual growth rate (CAGR), from $188.6M to $173.65M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Enovis's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude